Subscribe

PRESS RELEASES

PAXMAN strengthens its market presence in Asia with distribution agreement for Pakistan

PAXMAN announces that the company has signed a distribution agreement for its market leading scalp cooling system in Pakistan with Lahore-based Varitron. The agreement increases PAXMAN’s global outreach with a market covering 220 million people and almost 200,000 new cancer cases annually.

Read More

PAXMAN receives market registration in South Africa for its latest PSCS scalp cooling system

PAXMAN announces that the company has received market registration in South Africa for the latest PSCS model of its scalp cooling system. Based on this, the company expects an increased order flow from its South African distributor Pharmacentrix during the rest of the year and in 2020.

Read More

Regulatory

PAXMAN receives order for 10 scalp cooling systems to Australia

PAXMAN announces that the company has received an order for 10 scalp cooling systems to Australia from its Oceanian distributor Regional Health Care Group. Earlier in June, financing for up to 10 scalp cooling systems to New Zealand via the same distributor was confirmed.

Read More

PAXMAN publishes newsletter on the company’s expansion in South America and a recently received design award

Today, PAXMAN publishes the June 2019 issue of its newsletter aimed at shareholders, investors and other interested parties.

Read More

Regulatory

PAXMAN receives market registration in Brazil for its latest scalp cooling system

PAXMAN announces that the company has received market registration in Brazil for the latest PSCS model of its scalp cooling system. The first orders of at least 8 systems in total are expected shortly. PAXMAN and its Brazilian distributor EPTCA Medical will host an official launch event for the new system at a medical congress in October.

Read More

Regulatory

Press release from PAXMAN AB’s 2019 Annual General Meeting

PAXMAN’s second AGM was held today, 23 May 2019, at NetPort in Karlshamn. Slightly more than 72 % of all issued shares were represented at the meeting. After the formal AGM, CEO Richard Paxman gave a company presentation and responded to questions from the attending shareholders.

Read More

Regulatory

PAXMAN publishes its interim report for Q1 2019

Steady financial improvements in combination with continued strong global growth

Read More

PAXMAN announces that bill for mandatory coverage of scalp cooling costs was rejected in Texas

PAXMAN announces that the bill, proposing mandatory insurance coverage of scalp cooling costs for cancer patients, was rejected by the Texas Senate after passing the House of Representatives. However, scalp cooling is now on the agenda in additional states, and similar bills are being prepared in New York and other states.

Read More

Regulatory

PAXMAN reaches milestone of 500 scalp cooling systems in the USA

PAXMAN announces that the company now has installed or signed delivery agreements for just over 500 scalp cooling systems preventing hair loss in connection with chemotherapy in the USA, only two years after receiving FDA approval. The company is now actively supporting large-scale coverage and reimbursement for the treatment.

Read More

PAXMAN publishes Annual Report for 2018

PAXMAN has now published its Annual Report for the financial year 2018.

Read More

PAXMAN announces that the state of Texas is preparing a bill proposing mandatory coverage of scalp cooling costs

PAXMAN announces that the state of Texas is preparing a bill that proposes mandatory coverage of scalp cooling costs in connection with chemotherapy by health care programs. The bill was addressed in a hearing before the House Committee on Insurance on April 16, and if it becomes legislation it would constitute an important step towards total cost coverage in the USA.

Read More

Regulatory

NOTICE OF THE ANNUAL GENERAL MEETING FOR PAXMAN AB

The shareholders of PAXMAN AB (publ) (”the Company”) are hereby invited to attend the Annual General Meeting on Thursday 23 May 2019 at 15:00 CET at meeting hall ”Amazonas”, NetPort, Biblioteksgatan 4, 374 35 KARLSHAMN. Registration will begin at 14:30 CET.

Read More

PAXMAN publishes newsletter on the company’s market approval in Japan

Today, PAXMAN publishes the April 2019 issue of its newsletter aimed at shareholders, investors and other interested parties.

Read More

Regulatory

PAXMAN receives order for 20 scalp cooling systems to Japan two weeks after market approval

PAXMAN announces that the company has received an order for 20 scalp cooling systems to Japan from its distributor Century Medical. The systems will be installed at Tokyo Medical Center Hospital and Kyoto University Hospital, with deliveries starting in June.

Read More

Regulatory

PAXMAN receives market approval in Japan, will initiate comprehensive marketing activities in 2019

PAXMAN announces that the company has received a market approval (Shonin) in Japan for its market leading scalp cooling system that prevents chemotherapy-induced hair loss. The approval covers all solid tumours, and the company will initiate comprehensive market activities in Japan in 2019 together with its distributor Century Medical.

Read More

Regulatory

Paxman AB (publ): The NCCN Guidelines now recommend scalp cooling as a category 2A treatment option for patients with invasive breast cancer

PAXMAN today announce that the National Comprehensive Cancer Network® (NCCN®) has updated the Clinical Practice Guidelines in oncology for breast cancer (Version 1.2019) to include scalp cooling as a Category 2A recommendation to reduce the incidence of chemotherapy-induced alopecia for patients receiving chemotherapy.

Read More

Regulatory

Paxman AB (publ): PAXMAN publishes its year-end report January – December 2018

After a strong fourth quarter PAXMAN exceeded its turnover target for 2018

Read More

Regulatory

Paxman AB (publ): PAXMAN and University of Huddersfield invest 12 MSEK over 5 years into world’s first scalp cooling research and development centre

PAXMAN and the University of Huddersfield have signed a five-year research and collaboration agreement covering the PAXMAN Scalp Cooling Research Centre, a new multidisciplinary research group at the University of Huddersfield. The centre will focus on biological hair follicle research as well as developing innovative scalp cooling-related treatments and individual 3D-printed cooling caps.

Read More

Paxman AB (publ): PAXMAN publishes newsletter on its new CIPN indication and the double win at the EEF Future Manufacturing Awards

Today, PAXMAN publishes the February 2019 issue of its newsletter aimed at shareholders, investors and other interested parties.

Read More

Regulatory

PAXMAN to develop medical cooling device to prevent nerve damage in chemotherapy patients with National University Hospital, Singapore

PAXMAN has signed a research collaboration agreement with National University Hospital, Singapore for the development of a portable cooling and compression device to prevent chemotherapy-induced peripheral neuropathy (nerve damage in hands and feet). The goal is to have a prototype ready for clinical studies in Q2 2020.

Read More

Regulatory

PAXMAN receives second order from Teva in Mexico following successful market launch

PAXMAN announces that the company’s license partner Teva Pharmaceutical has ordered ten additional scalp cooling systems for Mexico after the successful market launch in November. Teva’s first order for 17 systems is currently being installed, with the first patient treatment at Centro Oncologico Internacional in Guadalajara last week.

Read More


PAXMAN to present the company at Stora Aktiedagen on 26 November

PAXMAN AB (publ) will give a company presentation at Stora Aktiedagen in Stockholm on 26 November. As the presentation takes place only a few days after the publication of the company’s Q3 report, PAXMAN’s CEO Richard Paxman will have the opportunity to give some more detailed comments on its contents.

Read More

Regulatory

PAXMAN publishes its interim report for the period 1 April to 30 June 2018

Continued expansion in line with business plan

Read More

Regulatory

PAXMAN receives first order from Teva in Mexico for 17 scalp cooling systems

PAXMAN announces that the company has received a first order from its license partner Teva Pharmaceutical Industries Ltd for 17 scalp cooling systems to Mexico. The systems are to be installed at five cancer centres, three of which will install systems in Mexico City.

Read More

PAXMAN comments on AMA decision on CPT code for scalp cooling

The AMA (American Medical Association) in the USA has decided not to introduce a specific CPT code that would facilitate patient cost reimbursement for scalp cooling at this time. The decision is largely based on the fact that the patient base is not yet considered to be sufficient. PAXMAN expects AMA to review its position as scalp cooling gradually becomes more common in the USA.

Read More

PAXMAN announces FDA clearance for an expanded indication of its scalp cooling system in the US

PAXMAN’s advanced scalp cooling system has now been cleared by the US Food and Drug Administration (FDA) for use during treatment of patients with solid tumours. The expanded FDA clearance substantially increases the potential number of new cancer patients per year that the system can be marketed to in the USA – from an estimated 250,000 breast cancer patients to over one million breast cancer and solid tumour cancer patients.

Read More

Press release from PAXMAN AB’s 2018 Annual General Meeting

PAXMAN’s first AGM was held today, 24 May 2018, at NetPort in Karlshamn. Slightly more than 83 % of all issued shares were represented at the meeting. After the formal AGM, CEO Richard Paxman gave a company presentation and responded to questions from the attending shareholders.

Read More


PAXMAN supplements application for expanded FDA clearance in the USA

PAXMAN AB (publ) has supplemented the company’s premarket notification application to the US FDA for an expanded indication by responding to a request for additional information. The application seeks to expand use of the company’s scalp cooling to reduce the likelihood of chemotherapy-induced alopecia (CIA) in cancer patients with solid tumors.

Read More

PAXMAN publishes Annual Report for 2017

PAXMAN hereby publishes its Annual Report for the financial year 2017.

Read More

PAXMAN amends acquisition value of Paxman Group Ltd and year-end figures

PAXMAN informs that the company has changed its accounting treatment regarding the acquisition of Paxman Group Limited.

Read More

PAXMAN receives market approval in Mexico and plans Q2 launch with license partner Teva Pharmaceutical Industries Ltd

PAXMAN announces that the company has received market approval in Mexico for its market leading scalp cooling system which reduces hair loss during chemotherapy treatment. PAXMAN and license partner Teva will now increase their activities in preparation for an official launch later in the second quarter.

Read More

NOTICE OF THE ANNUAL GENERAL MEETING FOR PAXMAN AB

The shareholders of PAXMAN AB (publ) (“the Company”) are hereby invited to attend the Annual General Meeting on Thursday 24 May 2018 at 15:00 CET at meeting hall “Zambesi”, NetPort, Biblioteksgatan 4, 374 35 KARLSHAMN. Registration will begin at 14:30 CET.

Read More

PAXMAN submits application for market approval in Japan

PAXMAN announces that the company has applied for a market approval (SHONIN) in Japan for its market leading scalp cooling system that reduce hair loss during chemotherapy treatment. The application covers all solid tumours including breast cancer.

Read More

PAXMAN reaches milestone of 250 scalp cooling systems in the USA, including a new agreement with a top ten-ranked cancer center

PAXMAN announces that the company has reached its target of installing or signing delivery agreements for at least 250 scalp cooling systems in the USA within one year after the FDA clearance in April 2017. The milestone was reached by signing a new agreement with a top ten-ranked cancer treatment center according to U.S. News & World Report’s annual ranking.

Read More

PAXMAN’s scalp cooling system available at all the five highest-ranked cancer centres in the USA

PAXMAN announces that the company now has signed delivery agreements in the USA for its leading scalp cooling system with all of the five highest-ranked cancer treatment centres according to U.S. News & World Report’s annual ranking. This important milestone was achieved by an agreement for four systems with the last remaining top-ranked cancer center.

Read More


PAXMAN and Teva Pharmaceutical Industries Ltd. announce licensing agreement for PAXMAN Scalp Cooler in the Mexico market

PAXMAN and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) have announced the signing of an exclusive licensing agreement for PAXMAN Scalp Cooler treatments in the Mexico market. Under the agreement, Teva will be responsible for the sales and marketing activities in Mexico.

Read More

PAXMAN receives a 10 MSEK line of credit as a financial buffer to enable increased expansion rate in the US

PAXMAN announces that the company has received a 10 MSEK line of credit to be used as a financial buffer for initial costs related to signed contracts in the United States, while at the same time being able to increase the rate of expansion on this important market. The line of credit is estimated to be more than sufficient until the PAXMAN group can deliver a positive cash flow.

Read More

PAXMAN publishes its Interim Report as of 30 September 2017

Continued growth and market expansion in the third quarter of the year.

Read More